Clinical Trials on Patient Recovering Maximum Walking Capacity, Over 10 Meters in United States
Total 0 results
Nothing found
Sponsors and Collaborators
- Mononuclear Therapeutics Ltd.
- Bruce County Paramedic Service
- Women and children's hospital of Jiaxing university
- Prestige Biopharma Limited
- Centro di Procreazione Assistita Demetra
- Grand Challenges Canada
- Bjørgene Omsorgssenter, Haugesund
- Yantai Yuhuangding Hospital，Medical College, Qingdao University
- BayCare Health System
- Equipe MiMes
- Veeda Oncology
- Chengdu Nuoen Biotechnologies, Inc.
- Maria Lendorf
- AIDS Council of New South Wales
- North Karelia Hospital District
- Neuregenix
- Reina Sofia University Hospital
- ImproveCareNow (ICN)
- Nestor Soler Porcar, MD, PhD
- InflaRx GmbH
- View Full List
Medical Conditions
- Chlamydophila Infections
- Pulmonary Adenocarcinoma
- Cutaneous Leiomyomata With Uterine Leiomyomata
- Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
- Skull Base Neoplasms
- Tay-Sachs Disease Ganglioside
- Epidemic Hemorrhagic Fever
- Fracture Dislocation of Cervical Spine
- Multisystem Proteinopathy
- Ewing's Family Tumors
- Psoriasis, Arthritic
- Gullian Barre Syndrome
- Endocarditis Infective
- Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
- Fetus or Neonate Affected by External Version Before Labor
- Painless Hysteroscopy
- Spine Surgeries
- Closure; Foramen Ovale
- Predictors of Atrial Fibrillation Recurrences
- Childhood Langerhans Cell Histiocytosis
- View Full List
Drug Interventions
- High dose pantoprazole infusion
- Redifferentiation with retinoid acid
- Esomeprazole 40mg before
- Cereport
- Adriamycin
- PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
- NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
- Semapimod
- Vehicle
- Estradiol+Drospirenone
- Adapalene Gel 0.3%
- Palliative care group first-line scheme
- Qingkailing injection 40 ml
- Chemotherapeutic Agent
- Neihulizumab
- Azelastine hydrochloride (BAYR9258)
- Glimepiride
- Naltrexone 50 mg/day + Cognitive Behavioral Therapy
- Mocetinostat - Recommended Phase 2 Dose (70 mg)
- EFV +TVA
- View Full List
CROs by country
- Contract Research Organizations in Burkina Faso
- Contract Research Organizations in Canada
- Contract Research Organizations in Dominican Republic
- Contract Research Organizations in Guatemala
- Contract Research Organizations in Israel
- Contract Research Organizations in Latvia
- Contract Research Organizations in Macedonia
- Contract Research Organizations in Netherlands
- Contract Research Organizations in Papua New Guinea
- Contract Research Organizations in Rwanda
- Contract Research Organizations in Ukraine
- Contract Research Organizations in Uruguay
- Contract Research Organizations in Zambia
- CRO list by country